Literature DB >> 1907901

Post-cardiac transplant reactivation of Chagas' disease diagnosed by skin biopsy.

L F Libow1, V P Beltrani, D N Silvers, M E Grossman.   

Abstract

Reactivation of Chagas' disease in immuno-compromised hosts may represent a recognizable clinical syndrome that can be diagnosed by examination of skin biopsy specimens of characteristic lesions resembling ordinary bacterial cellulitis. This syndrome appears to result in significant morbidity, which can be avoided with the institution of prophylactic therapy for Chagas' disease. An awareness of this complication of immunosuppression is of paramount importance for the thousands of asymptomatic persons infected with Chagas' disease currently living in the United States and abroad.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907901

Source DB:  PubMed          Journal:  Cutis        ISSN: 0011-4162


  5 in total

Review 1.  Infections in solid-organ transplant recipients.

Authors:  R Patel; C V Paya
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

Review 2.  Infection in the bone marrow transplant recipient and role of the microbiology laboratory in clinical transplantation.

Authors:  M T LaRocco; S J Burgert
Journal:  Clin Microbiol Rev       Date:  1997-04       Impact factor: 26.132

3.  Hydroxymethylnitrofurazone treatment in indeterminate form of chronic Chagas disease: Reduced intensity of tissue parasitism and inflammation-A histopathological study.

Authors:  Cauê B Scarim; Cleverton R de Andrade; João A da Rosa; Jean L Dos Santos; Chung M Chin
Journal:  Int J Exp Pathol       Date:  2018-10-15       Impact factor: 1.925

Review 4.  Chagas' disease.

Authors:  H B Tanowitz; L V Kirchhoff; D Simon; S A Morris; L M Weiss; M Wittner
Journal:  Clin Microbiol Rev       Date:  1992-10       Impact factor: 26.132

5.  Cysteine protease inhibitors cure an experimental Trypanosoma cruzi infection.

Authors:  J C Engel; P S Doyle; I Hsieh; J H McKerrow
Journal:  J Exp Med       Date:  1998-08-17       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.